Biotechnology Assets Stock

Biotechnology Assets Equity

The The Equity of Biotechnology Assets (BST.MC) as of Aug 2, 2026 is 6.18 M EUR. In the previous year, The Equity was 6.61 M EUR — a change of -6.56% (lower).

Equity

6.18 MEUR

YoY

-6.56%

Last updated:

In 2026, Biotechnology Assets's equity was 6.18 M EUR, a -6.56% increase from the 6.61 M EUR equity in the previous year.

Access this data via the Eulerpool API

Biotechnology Assets Stock analysis

What does Biotechnology Assets do? ADL Bionatur Solutions SA is a Swiss company specializing in the development and production of natural ingredients for the food, cosmetics, and pharmaceutical industries. The company was founded in 2000 and has since had an impressive success story. ADL Bionatur Solutions SA's business model is based on the use of plants and microorganisms to extract high-quality natural active ingredients. The company employs environmentally friendly methods and sustainable production practices that meet the needs of society and nature alike. One of ADL Bionatur Solutions SA's main sectors is the production of natural flavors and colorants for the food industry. Depending on customer preferences, color pigments are extracted from fruits, vegetables, or other plants to color food products with natural ingredients. Natural flavors are also isolated using plant extracts and other natural sources. These products are particularly sought after because they are not only healthier than synthetic alternatives but also provide consumers with a better feeling. Another significant sector of ADL Bionatur Solutions SA is the development of cosmetics based on natural ingredients. For example, extracts from algae, flowers, or herbs are used to create skincare products that are gentle on the skin while still being highly effective. Products targeting signs of aging or acne are also based on natural ingredients from ADL Bionatur Solutions SA. In addition to these two main sectors, ADL Bionatur Solutions SA also offers products for the pharmaceutical industry. The company focuses on developing active ingredients based on natural substances that can be used to treat various diseases. Sustainability is also a key focus here, as naturally derived active ingredients are not only healthier but also have a higher biological availability. In addition to these main sectors, ADL Bionatur Solutions SA provides consulting services to customers. This includes the development of tailored natural solutions and support for product certification according to the highest international standards. Overall, in recent years, ADL Bionatur Solutions SA has become one of the world's leading companies in the field of natural ingredients. With a wide portfolio of products and services and a strong focus on sustainability and environmental compatibility, the company is well-positioned to benefit from the ongoing trend towards natural and healthier products. Biotechnology Assets is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Biotechnology Assets's Equity

Biotechnology Assets's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Biotechnology Assets's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Biotechnology Assets's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Biotechnology Assets's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Biotechnology Assets’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Biotechnology Assets stock

The Equity of Biotechnology Assets is 6.18 M EUR in 2026.

Access this data via the Eulerpool API

Balance Sheet — Biotechnology Assets

All Key Metrics — Biotechnology Assets